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Background: To provide information on dose–response and aid in modelling the exposure dynamics of the BSE
epidemic in the United Kingdom groups of cattle were exposed orally to a range of different doses of brainstem
homogenate of known infectious titre from clinical cases of classical bovine spongiform encephalopathy (BSE).
Interim data from this study was published in 2007. This communication documents additional BSE cases, which
occurred subsequently, examines possible influence of the bovine prion protein gene on disease incidence and
revises estimates of effective oral exposure.
Findings: Following interim published results, two further cattle, one dosed with 100 mg and culled at 127 months
post exposure and the other dosed with 10 mg and culled at 110 months post exposure, developed BSE. Both
had a similar pathological phenotype to previous cases. Based on attack rate and incubation period distribution
according to dose, the dose estimate at which 50% of confirmed cases would be clinically affected was revised
to 0.15 g of the brain homogenate used in the experiment, with a 95% confidence interval of 0.03–0.79 g.
Neither the full open reading frame nor the promoter region of the prion protein gene of dosed cattle appeared
to influence susceptibility to BSE, but this may be due to the sample size.
Conclusions: Oral exposure of cattle to a large range of doses of a BSE brainstem homogenate produced disease
in all dose groups. The pathological presentation resembled natural disease. The attack rate and incubation period
were dependent on the dose.
Keywords: Bovine spongiform encephalopathy, BSE, Cattle, Oral dose, Dose–response, Attack rate,
Incubation period, Model, Risk of infection, Prion protein geneFindings
Background
To provide information on dose–response, minimum in-
fective dose and aid in modelling the exposure dynamics
of the BSE epidemic in the United Kingdom (UK) a
study was conducted to determine the attack rate and
dose response of cattle orally exposed to a range of dif-
ferent doses of classical bovine spongiform encephalop-
athy (BSE) brainstem homogenate of known infectious
titre [1]. Although interim findings of this study have
been published [1], the data presented for the second* Correspondence: timm.konold@ahvla.gsi.gov.uk
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reproduction in any medium, provided the orphase of the study were incomplete because of survival
of some dosed cattle at the time (December 2006). The
objective of this update is to present the completed data
following termination of the second phase of the study,
to document additional sequencing of the bovine prion
protein gene (PRNP) of the studied cattle, with a pos-
sible influence on the incidence of disease, and to intro-
duce a minor revision of the dose–response model given
the occurrence of further BSE cases among recipients.Methods
All procedures involving cattle were approved under the UK
Animal (Scientific Procedures) Act 1986 under licence from
the Home Office of the UK government.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The experimental design has been described in detail
previously [1]. Briefly, groups of calves were dosed orally
with a pool of BSE brainstem homogenate: 100 g on
three consecutive days or single doses of 100 g, 10 g
or 1 g (first phase) and 1 g, 100 mg, 10 mg, or 1 mg
(second phase). The end point titre of the BSE brainstem
homogenate, assayed in RIII mice, was 103.5 mouse
intracerebral/intraperitoneal (i.c./i.p.) ID50/g.
Clinical monitoring
Clinical assessment methods, which varied between the
study phases because of operational differences, have
been described previously [1]. As previously the clinical
status was categorised as possible, probable or definite
signs of BSE [2] by the same assessor to allow compar-
ability of study phases.
Cull and postmortem examinations
Animals were culled after the display of definite signs of
BSE, other untreatable conditions that required euthan-
asia or from 144 months post exposure (mpe), which
was the study end-point. This end-point was estimated
to encompass all incubation periods (IPs = time from
exposure to display of definite signs of BSE or death
whichever occurred earlier) with 95% probability based
on interim data analysis of the IPs of all BSE cases in
this study, which suggested that the IP would follow a
log-normal distribution depending on dose (see below).
Postmortem examinations, including histopathology and
immunohistochemical examination for the presence of
disease-associated prion protein (PrPd), were as described
previously for the second phase of the study [1].
Western immunoblotting (WB) for the proteinase-
resistant form of the prion protein (PrPres) was pre-
viously carried out with the Prionics-Check Western
technique (Prionics AG, Schlieren, Switzerland) [3], but
was replaced for the present study with the BioRad
TeSeE Western blot test (BioRad Laboratories, Marnes-
La-Coquette, France) using the mAb Sha31 (BioRad
Laboratories) [4] instead of mAb 6H4 (Prionics AG).
Genotyping
Analysis of the bovine PRNP of the cattle was extended
to include the promoter region and full open reading
frame (ORF) from EDTA blood samples (live animal),
semitendinosus muscle or brain (culled animal). DNA
was extracted and amplified by polymerase chain reac-
tion (PCR) as published previously [5] to determine
bovine ORF polymorphisms and compare it to a wild-
type PrP gene reference sequence from a Jersey cow,
GenBank accession number AJ298878 [6].
To detect bovine PrP promoter 23 and 12 base pair
(bp) insertions and deletions (indels), which have beeninvestigated in association with BSE incidence [7], a
TaqMan allelic discrimination assay was designed, opti-
mised and performed, for each indel based on guidelines
set out for designing TaqMan probes and primers (TaqMan
Universal PCR Master Mix Protocol, Applied Biosystems,
Foster City, USA). Forward and reverse PCR primer were
5'-CGGTTTTACCCTCCTGGTTAGG-3' and 5'-CCAC
CCACATACCTCGGG-3' for genotyping the 12-bp indel
and 5'-GCCCAGGTGCCAGCC-3' and 5'-AAGAGTTG
GACAGGCACAATGG-3' for the 23-bp indel. Fluorogenic
probe (Applied Biosystems) sequences were 5’-CGGCC
CCCGCCCACATTC-3’ and 5’-ACCAGCCAGCCCACAT
TCCGAGTAA-3’ for the 12-bp indel as well as 5’-AA
TCTCAGATGTCTTCCCAACAGCAGCC-3’ and 5’-CCT
AGCTATCACGTCAAGCCTCAGACG-3’ for the 23-bp
indel. The data were analysed by Sequence Detector Soft-
ware (SDS) version 1.9.1 (Applied Biosystems).
The promoter and ORF regions of PRNP were
assessed in 26 cattle from the first phase of the study
for which tissue was available for testing [seven BSE-
positive and three BSE-negative (at study termination at
100 mpe) cattle dosed with 1 g, five BSE-positive and
two BSE-negative (at study termination at 100 mpe)
cattle dosed with 10 g and nine BSE-positive cattle dosed
with 100 g] and all 60 cattle from the second phase of
the study.Effect of dose and genotype on probability of infection
and incubation period
Data on the IP for each animal exposed to single doses
and on the survival of the non-affected animals were
used to estimate the dependence of both the IP distribu-
tion and attack rate on the dose, via maximum likeli-
hood. Based on the assumption that the IP followed a
log-normal distribution, with the mean depending
linearly on the log dose, d, and that the attack rate fol-
lowed a logistic regression curve, the maximum likeli-
hood estimates of the parameters for the IP distribution
and probability of infection according to dose (expressed
in terms of mouse i.c./i.p. ID50) could be calculated
using previously published formulae [1].
Proportional hazard (Cox) regression (Statistica ver-
sion 10, StatSoft Inc., Tulsa, USA) was used to evaluate
the effect of genotype and dose of inoculum on the sur-
vival of cattle inoculated with the BSE agent. The
dependent variable was the time of cull/onset of definite
signs, whereas independent variables were the dose
(as log10), the octapeptide repeats (6:6 compared to
others), the silent PrP ORF polymorphisms (homozygous
or heterozygous compared to wild type) and the 12 and
23 bp indels (+/+, +/− and −/− compared). All dosed
BSE-negative cattle were censored according to their age
at cull.
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Previously published results of the first phase of the
study established BSE in all ten cattle dosed with
3×100 g (IP range: 33–45 mpe) and 100 g (IP range: 31–
60 mpe), in seven of nine cattle dosed with 10 g (IP
range 41–72 mpe, the tenth died of an intercurrent dis-
ease at 14 mpe), and in seven of ten cattle dosed with
1 g (IP range: 45–72 mpe) [1]. In the second phase in-
terim published results reported BSE in three of four
cattle dosed with 1 g (IP range: 58–73 mpe), in seven of
fifteen dosed with 100 mg (IP range: 53–98 mpe) and in
single cattle from groups of fifteen dosed with 10 mg
(IP: 56 mpe) or 1 mg (IP: 68 mpe).
After publication of the interim findings, two further
cases of BSE were diagnosed in cattle in the second
phase, one dosed with 100 mg and the other with
10 mg. For completeness of the data from the second
phase the times from exposure to onset of the different
clinical stages and cull for all BSE-positive cases are
given in Table 1 and for all other cattle where BSE was
excluded by postmortem tests in Table 2. Neuropatho-
logical examination confirmed a vacuolar profile in the
brain of the case dosed with 10 mg consistent with that
reported previously in the study and with that of natur-
ally affected cattle [1]. The animal dosed with 100 mg
and culled with spastic syndrome did not present withTable 1 Times from exposure to onset of stages and cull








1 g dose group
CM917 55 56 58 59
CN944 53 62 64 65
CM897 62 68 73 73
100 mg dose group
CN938 49 52 53 56
CM900 49 50 53 58
CN951 58 59 62 63
CM909 45 50 74 75
CM936 62 –– 75 77
CM934* 62 74 90 90
CN942 61 97 98 98
CN954*† 50 127 –– 127
10 mg dose group
CM898 49 50 56 58
CM923 62 107 109 110
1 mg dose group
CN947 56 62 68 70
All cattle belonged to the second phase of the study.
Times are displayed in months.
* No vacuolar changes in the brain.
† Culled because of spastic syndrome.vacuolar changes in the brain but in both cases the diag-
nosis of BSE was confirmed by detection of PrPd immu-
nohistochemically and PrPres on WB.
The clinical duration in confirmed BSE cases (time
from onset of possible signs to cull, excluding those ani-
mals that were culled prior to displaying definite signs)
ranged from 4 months (CM917 dosed with 1 g) to
48 months (CM923 dosed with 1 mg). Although there
was a tendency of cattle exposed to extremely high doses
(3× or single dose of 100 g) to have a shorter clinical
duration compared to lower doses [median (range;
standard deviation) for 3×100 g: 9 (5–18, 4.5), for 100 g:
13 (6–33; 8.7), for 10 g: 18 (11–43; 13.0), for 1 g:
18.5 (4–32; 8.9) and for 100 mg: 15 (5–37; 12.8) months;
see [1] and Table 1], the difference was not statistically
significant (P = 0.08, Kruskal-Wallis test, GraphPad
Prism version 5, GraphPad Software, La Jolla, USA).
Determination of the exact clinical onset to estimate
clinical duration is invariably subjective because it is
often based on the display of behavioural changes that
may also occur to some extent in “normal” cattle, as
observed in undosed controls in this study, even in the
absence of another underlying condition. It is for this
reason that throughout the study IP has been defined on
the basis of onset of definite signs.
No novel polymorphisms were detected in the ORF
regions of the 86 tested cattle. Variations in the number
of N-terminal octapeptide repeats among PrP gene
sequences were reported previously [1]. The other ORF
DNA polymorphisms detected were silent in that they
do not result in an amino acid change. A summary of
the results is given in Table 3. The findings were consist-
ent with those reported previously [5]. Five common
promoter genotypes were identified in this study, with
the sixth (23 bp −/−, 12 bp +/+) being relatively rare
(only found in one animal, see Table 3), which is consist-
ent with previous findings [7]. Proportional hazard re-
gression analysis using the data from 76 orally dosed
cattle revealed that the dose was the most important
predictor of hazard (P < 0.0001), which was expected,
whereas none of the genotype parameters were signifi-
cant predictors (P > 0.3). In other words, the main factor
that determined how rapidly orally dosed cattle suc-
cumbed to BSE was the dose of inoculum, and the geno-
type did not appear to have a significant influence.
Whilst it has been reported that homozygous carriers of
the 12 bp insertion allele (12 bp +/+) have a lower risk
of developing natural BSE [7], this promoter genotype
did not appear to reduce susceptibility to oral exposure
to BSE. This may be due to sample size in the current
study: to have a reasonable power (80%) to detect the
differences (20.5%) as observed by Juling et al. [7], for
UK Holstein cattle sample sizes of 60 (12 bp +/+) and
210 (12 bp +/− or −/−) would have been required.
Table 2 Times from exposure to onset of stages and cull with experimental outcome in BSE-negative cattle
Animal identity Possible signs Probable signs Definite signs Cull Experimental outcome
1 g dose group
CN939 49 –– –– 53 Spastic syndrome
CM933 56 –– –– 144*
100 mg dose group
CN950 –– –– –– 97 Urethral obstruction
CM921 –– –– –– 100 Hip injury
CN946 117 –– –– 144 Died, no cause identified
CM906 –– –– –– 145*
CM914 –– –– –– 145*
CN948 –– –– –– 145*
CN949 –– –– –– 145*
10 mg dose group
CN952 –– –– –– 84 Indigestion?
CM915 –– –– –– 85 Metabolic disease
CM929 71 –– –– 101 Muscle trauma
CM919 –– –– –– 119 Osteoarthrosis
CM931 –– –– –– 123 Osteoarthrosis
CN941 65 –– –– 126 Recumbency, hypophosphataemia
CM904 53 –– –– 136 Recumbency, thyroid adenoma
CM899 –– –– –– 144*
CM916 47 –– –– 144*
CM924 138 –– –– 144* Compressive spinal cord lesion
CM913 –– –– –– 145*
CM928 –– –– –– 145*
CN943 –– –– –– 145*
1 mg dose group
CM922 64 –– –– 81 Renal failure
CM932 –– –– –– 103 Died, no cause identified
CM926 –– –– –– 104 Urethral obstruction
CN955 –– –– –– 109 Died – indigestion?
CM910 73 –– –– 112 Osteoarthrosis
CM907 –– –– –– 123 Spastic syndrome
CM920 94 –– –– 125 Osteoarthrosis
CM930 –– –– –– 136 Recumbency, meningeal tumour
CM905 62 –– –– 144*
CN940 –– –– –– 144*
CM896 –– –– –– 145*
CM903 62 –– –– 145*
CN937 106 –– –– 145* Hippocampal lesion (focal dysplasia)
CN945 127 –– –– 145*
Undosed controls
CM908 –– –– –– 39 Vertebral fracture
CM918 62 –– –– 97 Pleural mesothelioma
CM925 –– –– –– 59 Femoral fracture
CM856 61 –– –– 101 Septic arthritis
CM858 71 –– –– 103 Muscle injury, spastic syndrome
CM901 56 –– –– 125 Chronic enteritis (Johne’s disease)
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Table 2 Times from exposure to onset of stages and cull with experimental outcome in BSE-negative cattle (Continued)
CM927 135 –– –– 144 Found dead (indigestion?)
CM935 32 –– –– 145*
CM859 117 –– –– 145*
CM902 –– –– –– 145*
All cattle belonged to the second phase of the study.
* Culled because of termination of study.
Times are displayed in months. For controls, months are displayed as months after test group exposure.
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BSE case (Table 1 and [1] for phase 1 of the study), the
probability of infection given the dose S (d) could
be expressed as: S(d) = exp(α+β*d)/(1+exp(α+β*d))
with parameters (and 95% confidence intervals) given
by α = −3.01 (−3.59, −2.44) and β = 1.12 (0.93, 1.33)
(see Figure 1), which is a slight modification to the
parameters reported previously (α = −3.50; β = 1.26 [1]),
and the additional data resulted in a revised estimate of
one cattle oral ID50 being equivalent to 10
2.7 mouse i.c./
i.p. ID50/g (with 95% confidence interval of 10
2.0, 103.4)
compared to the previous estimate of 102.8 mouse i.c./i.p.
ID50/g (with 95% confidence interval of 10
2.1, 103.5). This
ID50 estimate is equivalent to 0.15 g of the brain hom-
ogenate used in the experiment (previous estimate:
0.20 g), with a 95% confidence interval of 0.03–0.79 g.




6:6 silent Q78 HET 28 (33%)
6:6 WT 25 (29%)
6:6 silent Q78 HOM 10 (12%)
6:5 silent Q78 HET 7 (8%)
6:6 silent N192 HET 5 (6%)
6:5 WT 4 (5%)
6:6 silent Q78 HET & silent N192 HET 3 (3%)
6:5 silent N192 HET 2 (2%)
5:5* WT 1 (1%)
6:6 silent P113 HET 1 (1%)
Promoter
23 bp +/− 12 bp +/− 31 (38%)
23 bp −/− 12 bp −/− 27 (33%)
23 bp +/+ 12 bp +/+ 10 (12%)
23 bp +/− 12 bp +/+ 8 (10%)
23 bp −/− 12 bp +/− 5 (6%)
23 bp −/− 12 bp +/+ 1 (1%)
Genotypes 5:5, 6:6 and 6:5 refer to the copies of octapeptide repeats, 23 bp and 12
N192 are silent polymorphisms, either homozygous (HOM) or heterozygous (HET) a
type (WT).
Four of the 86 cattle were excluded from the comparison of the promoter region b
* Exposed to 1 g in the first phase of the study and erroneously reported as having102.7 cattle i.c. ID50 [8], it can be extrapolated that one
cattle oral ID50 equals 10
5.4 cattle i.c. ID50, (previously
estimated at 105.5 cattle i.c. ID50).
The IP followed a lognormal distribution with para-
meters of μ = a−b×log10(dose), with a = 4.66 (4.54, 4.71)
and b = 0.14 (0.13, 0.17), and σ = 0.23 (previously: μ =
4.54−0.14×log10(dose), σ = 0.21), where dose is the titre
of brain homogenate in terms of mouse i.c./i.p. ID50/g
[see Figure 2, which shows the association between
mean IP (given by exp(μ+0.5σ2) and the dose].
Preliminary findings from the original study contribu-
ted to quantitative risk assessment of the exposure of
humans to consumption of infected bovine products [9].
An estimate of human ID50 assumed the worst case of a
cattle to human species barrier of a factor of one, giving
the range of human oral ID50s in 1 g of brain from a























bp are the indels (− = deletion allele, + = insertion allele), Q78, P113 and
t position 78, 113 and 192 of the ORF respectively compared to the wild
ecause of an inconclusive assay result for the 23-bp indel.
a 6:6 genotype previously [1].
Figure 1 Estimated probability of infection given the dose of
brain homogenate used in the study. The probability of infection
given the dose S(d) could be expressed as: S(d) = exp(−3.01+1.12*d)/
(1+exp(−3.01+1.12*d)), which results in the updated graph displayed
as continuous line. For comparison, the previous graph based on
interim data is displayed as dotted line, as published in 2007 [1].
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this estimate to 1.0 to 20 and additional results in the
present study indicate that this range should now be
revised to 1.3 to 33.3, although, as previously, it could be
greater with higher titres of BSE affected brain than used
in the present study. These estimates have been used to
assess the impact of BSE control measures on potential
consumption of BSE infectivity (BSE control modelFigure 2 Estimated mean incubation period according to dose of bra
continuous line is based on the current data. The previous graph based on
line for comparison.[10]). Although the reduced ID50 based on the present
results would increase estimates of the exposure of
humans in terms of bovine oral ID50s, the effect would
be comparatively small relative to the uncertainty in
such risk assessments. Nevertheless, with decline of the
BSE epidemic and the potential for relaxation of certain
controls, the revised estimate of human oral ID50 is
available to revisit risk assessments.
The present data do not affect the previous approxi-
mation that single doses in the range from 100 mg to
1 g of the brainstem homogenate used correspond to the
range of mean IPs of cattle through the BSE epidemic
[1]. The observation that a relatively small, single expos-
ure (less than 1 g of high titre brain) can result in
infection reinforces the importance of preventing cross-
contamination during feed ingredient storage and feed
production. This proved to be problematical in feed
mills producing ruminant and non-ruminant feedstuffs
as is evident from the incomplete effect of the initial
statutory control on the feeding of meat and bone meal
to ruminants introduced in the UK in 1988. The low
dose phenomenon, together with the persistent viability
of the BSE agent, has required the removal of specific
high risk tissues from cattle at slaughter and the total
ban on the use of mammalian meat and bone meal for
use in farmed livestock [11].
Conclusions
The present results concur with the interim findings of
this study, that the oral exposure of cattle to BSE brainin homogenate used in the study. The updated graph displayed as
interim data was published in 2007 [1] and is displayed as dotted
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attack rate such that in general the higher the dose the
shorter the IPs and the greater the attack rate. In all
cases the induced disease closely resembled the path-
ology of the natural disease. This is in keeping with the
analysis of the pathology in orally dosed cattle from
another study [12] and reinforces the validity of the oral
exposure model for the study of classical BSE in the
natural host. The estimate of a cattle oral ID50 is revised
to 0.15 g brain material used for the studies. Decline
of the BSE epidemic indicates that the use of a revised
estimate of human oral ID50 in risk assessments is, in
future, likely to contribute mainly to reassessments in
relation to possible relaxation of controls.
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